Oncology
Bevacizumab
Brand: Vegzelma
PBAC's latest decision on Bevacizumab: Recommended (2024). Considered for Metastatic colorectal cancer, locally recurrent or metastatic breast cancer, advanced/metastatic/recurrent non-squamous non-small cell lung cancer, advanced and/or metastatic renal cell cancer, grade IV glioma, epithelial ovarian/fallopian tube/primary peritoneal cancer, recurrent epithelial ovarian/fallopian tube/primary peritoneal cancer, and cervical cancer.
PBAC outcome
Recommended
Unrestricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
16
first 2008
PBS spend
$63M
68,634 scripts · 2024
Eligible population Patients with metastatic colorectal cancer, locally recurrent or metastatic breast cancer, advanced/metastatic/recurrent non-squamous non-small cell lung cancer, advanced and/or metastatic renal cell cancer, grade IV glioma, epithelial ovarian/fallopian tube/primary peritoneal cancer, recurrent epithelial ovarian/fallopian tube/primary peritoneal cancer, and cervical cancer.
Therapy area Oncology Line of therapy Not applicable Evidence base RCT Primary endpoint Surrogate Key trials NCT03247673, NCT03676192 Comparator Avastin (reference brand bevacizumab); other PBS-listed bevacizumab biosimilars (Abevmy, Bevaciptin, Mvasi) Economic model Cost-minimisation ICER note Cost-minimisation analysis performed; no ICER calculated by design ICER (historical) $45k/QALY–$75k/QALY across 6 submissions (2008–2016) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs. PBS expenditure
The Australian government paid $63M in PBS benefits for Bevacizumab in 2024 across 68,634 scripts, at $922 per script.
Submission history Mar 2008 : Not recommended · Authority Required — ICER $200k/QALYJul 2008 : Recommended with restriction · Authority Required — ICER $75k/QALYNov 2010 : Not recommended — ICER $105k/QALYMar 2011 : Not recommended · Authority Required — ICER $200k/QALYNov 2013 : Recommended with restriction · Authority RequiredMar 2014 : Not recommended · Restricted — ICER $105k/QALYNov 2015 : Recommended with restriction · Authority RequiredMar 2016 : Not recommended · Authority Required — ICER $75k/QALYMar 2019 : Recommended with restriction · Authority RequiredMay 2019 : Recommended with restriction · Authority RequiredJul 2020 : Recommended · Authority RequiredNov 2020 : Recommended · Authority RequiredMar 2021 : Recommended with restriction · UnrestrictedNov 2021 : Recommended · UnrestrictedMar 2022 : Recommended · UnrestrictedMar 2024 : Recommended · UnrestrictedSimilar precedents
Open on full dashboard →
Part of script.report — an independent tracker of every PBAC Public Summary Document and the PBS expenditure that follows. Built from public data on pbs.gov.au . Not affiliated with the Australian Department of Health, PBAC, or any pharmaceutical company.
script.report extracts information discussed in PBAC Public Summary Documents (PSDs), not independently calculated values. Where figures such as ICERs are shown, they reflect what was discussed or referenced in committee documentation — not confirmed inputs. For authoritative cost-effectiveness data, refer to the original PSD.